Background
- Early data suggests that cooccurring genetic events define biological heterogeneity in K-RAS mutant NSCLC, with K-RAS/ TP-53 co-mutated (KP) subset having potential therapeutic vulnerabilities to anti-PD-1 therapy with (A) improved response rates and (B) durable clinical benefit.
- To explore the immunological basis for these findings, we evaluated the immune biomarker profile (TMB/PDL1) in KP mutant m-NSCLC using a large next-generation sequencing (NGS) dataset.